Janus Kinase (JAK) Inhibitor
Upadacitinib for Juvenile Arthritis
Recruiting1 awardPhase 1
Chicago, Illinois
This trial is testing a medication called upadacitinib in children with a type of arthritis that affects many joints. The study aims to see how the drug behaves in their bodies, how safe it is, and how well they can tolerate it. Upadacitinib works by reducing inflammation and pain by blocking certain enzymes in the body. It has been approved for treating rheumatoid arthritis in adults.
Monoclonal Antibodies
Sarilumab for Juvenile Idiopathic Arthritis
Recruiting1 awardPhase 2
Calgary, Alberta
This trial is testing sarilumab, a medication that reduces inflammation, in children and teenagers with a specific type of arthritis called sJIA. The medication works by blocking a protein that causes inflammation.
Anti-metabolites
Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing whether a reduced-intensity conditioning regimen followed by umbilical cord blood transplant, double cord blood transplant, matched unrelated donor bone marrow transplant, or peripheral blood stem cell transplant is effective in treating patients with non-malignant disorders.
Behavioral Intervention
Multidisciplinary Care for Rheumatoid Arthritis
Recruiting1 award
Torrance, California
This trial will test a new intervention for socioeconomically disadvantaged Hispanic adults with rheumatoid arthritis to see if it improves remission rates. The intervention is based on a partnership between the patient and the extended healthcare team, and includes things like self-management education and technology-based at-home monitoring of symptoms.
Popular Filters
Trials for Rheumatoid Arthritis Patients
Biological Response Modifier
DMARDs for Rheumatoid Arthritis
Recruiting2 awardsPhase 3
Omaha, Nebraska
This trial is testing whether a certain type of arthritis medication can help predict clinical responses to other types of arthritis medication. All patients will receive a starting dose of the medication being tested, which may be adjusted by the investigator as needed. If a subject becomes intolerant to the medication being tested, the subject will be withdrawn from the study. Data from the study will be collected at the end of the trial.
Janus Kinase (JAK) Inhibitor
Long-Term Safety of Filgotinib for Rheumatoid Arthritis
Recruiting2 awardsPhase 3
Huntsville, Alabama
This trial aims to check the ongoing safety and tolerability of filgotinib, a medication that helps reduce inflammation and pain. The study focuses on people with rheumatoid arthritis who have already used filgotinib in a previous study. Filgotinib works by blocking enzymes that cause inflammation, helping to reduce swelling and pain. Filgotinib has been approved for the treatment of rheumatoid arthritis in adults who respond inadequately to other treatments in Europe and Japan.
Trials for RA Patients
Biological Response Modifier
DMARDs for Rheumatoid Arthritis
Recruiting2 awardsPhase 3
Omaha, Nebraska
This trial is testing whether a certain type of arthritis medication can help predict clinical responses to other types of arthritis medication. All patients will receive a starting dose of the medication being tested, which may be adjusted by the investigator as needed. If a subject becomes intolerant to the medication being tested, the subject will be withdrawn from the study. Data from the study will be collected at the end of the trial.
Janus Kinase (JAK) Inhibitor
Long-Term Safety of Filgotinib for Rheumatoid Arthritis
Recruiting2 awardsPhase 3
Huntsville, Alabama
This trial aims to check the ongoing safety and tolerability of filgotinib, a medication that helps reduce inflammation and pain. The study focuses on people with rheumatoid arthritis who have already used filgotinib in a previous study. Filgotinib works by blocking enzymes that cause inflammation, helping to reduce swelling and pain. Filgotinib has been approved for the treatment of rheumatoid arthritis in adults who respond inadequately to other treatments in Europe and Japan.
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Upadacitinib + Tocilizumab for Juvenile Idiopathic Arthritis
Recruiting2 awardsPhase 3
Portland, Oregon
This trial is evaluating a potential new treatment for juvenile idiopathic arthritis, a chronic disease that affects children and can continue into adulthood. Participants will receive either upadacitinib or tocilizumab and be assessed for adverse events and disease activity.
Biological Response Modifier
DMARDs for Rheumatoid Arthritis
Recruiting2 awardsPhase 3
Omaha, Nebraska
This trial is testing whether a certain type of arthritis medication can help predict clinical responses to other types of arthritis medication. All patients will receive a starting dose of the medication being tested, which may be adjusted by the investigator as needed. If a subject becomes intolerant to the medication being tested, the subject will be withdrawn from the study. Data from the study will be collected at the end of the trial.
Janus Kinase (JAK) Inhibitor
Long-Term Safety of Filgotinib for Rheumatoid Arthritis
Recruiting2 awardsPhase 3
Huntsville, Alabama
This trial aims to check the ongoing safety and tolerability of filgotinib, a medication that helps reduce inflammation and pain. The study focuses on people with rheumatoid arthritis who have already used filgotinib in a previous study. Filgotinib works by blocking enzymes that cause inflammation, helping to reduce swelling and pain. Filgotinib has been approved for the treatment of rheumatoid arthritis in adults who respond inadequately to other treatments in Europe and Japan.
Trials With No Placebo
Stem Cell Therapy
Stem Cells for Juvenile Arthritis
Recruiting1 awardPhase 2
Sugar Land, Texas
"This trial aims to test the safety and effectiveness of multiple intravenous infusions of stem cells in treating juvenile idiopathic arthritis. The study will involve 66 subjects and will last for 8 weeks per
Behavioural Intervention
Diet Intervention for Juvenile Arthritis
Recruiting1 award1 criteria
Winnipeg, Manitoba
This trial aims to investigate whether a Mediterranean Diet-based diet can improve arthritis in children by studying its effects on the gut microbiome. Fifty-four participants will change their diet for 8 weeks, with the
Janus Kinase (JAK) Inhibitor
Upadacitinib + Tocilizumab for Juvenile Idiopathic Arthritis
Recruiting2 awardsPhase 3
Portland, Oregon
This trial is evaluating a potential new treatment for juvenile idiopathic arthritis, a chronic disease that affects children and can continue into adulthood. Participants will receive either upadacitinib or tocilizumab and be assessed for adverse events and disease activity.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.